Please provide your email address to receive an email when new articles are posted on . Guselkumab produced consistent effects among biologic-naïve patients with PsA and those responded inadequately ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

SAN DIEGO – New research suggests more than one in five “opioid-naïve” patients continue to use the pain medication three months after having a procedure, underscoring the often-overlooked role ...

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and CanadaC-BEYOND Topline Results Expected ...

There is a significant unmet need for additional treatment options for high-grade NMIBC, especially in those ineligible for BCG.

Treatment-naive patients show greater BMD gains taking romosozumab than do patients who had previous antiresorptive treatments. "We conclude that prior antiresorptive therapy, particularly the ...

The effect of dupilumab was investigated among patients with severe and uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Among patients who did or did not undergo surgery to treat their ...

Patients with first-episode MDD showed lower effective and functional connectivity between the anterior cingulate cortex and frontal regions.

FLORHAM PARK, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s ...

A drug-drug interaction (DDI) study to assess the effect of oral galeterone on the pharmacokinetics (PK) of oral midazolam. This is an ASCO Meeting Abstract from the 2016 Genitourinary Cancers ...